# Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

> **NCT02232386** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 156 (actual)

## Conditions studied

- Chronic Lymphocyte Leukemia
- Adult Patients

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02232386
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-02
- **Primary completion:** 2018-04
- **Final completion:** 2024-04-16
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232386, "Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02232386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*